The article by [@b16-ehp0113-a00504] in this issue of *Environmental Health Perspectives* reignites the issue of the role that phthalate exposure during pregnancy may play in the etiology of reproductive disorders in human males. It does so by providing the first evidence of an association between phthalate exposure of mothers during pregnancy and attenuation of androgen action in their male babies. If this association is indicative of cause and effect, it will join together three key areas of research, namely, testicular dysgenesis syndrome (TDS) disorders in human males, induction of TDS-like disorders by phthalate administration to laboratory animals during pregnancy (experimental studies), and the widespread exposure of humans to various phthalates.

TDS refers to a collection of disorders of newborn or young adult males thought to have a common origin in fetal life as a result of testicular dysgenesis ([@b15-ehp0113-a00504]). These disorders include cryptorchidism (testis maldescent) and hypospadias, the two most common congenital malformations in newborns (2--4% and 0.3--0.7% incidence, respectively), testicular germ cell cancer, and low sperm counts. Low sperm count affects approximately 20% of young men in many European countries ([@b5-ehp0113-a00504]), whereas testicular cancer is the most frequent cancer of young men, and its incidence has been increasing progressively in Caucasian men for the past 50 years or more ([@b11-ehp0113-a00504]). An integral feature of the TDS hypothesis is hormonal dysfunction of the fetal testis, in particular, reduced production of testosterone ([@b13-ehp0113-a00504]). Because testosterone is largely responsible for transforming the fetus into a male, TDS can be viewed as a sexual differentiation (i.e., masculinization) disorder. But where do phthalates come in?

Studies by several groups have shown that exposing pregnant rats to certain phthalates (di-*n*-butyl, diethylhexyl phthalate or butyl benzyl phthalate) during the period of sexual differentiation of the pups results in a collection of disorders in the male offspring similar to TDS disorders in men ([@b3-ehp0113-a00504]; [@b8-ehp0113-a00504]). More tellingly, the phthalate exposure results in focal testicular dysgenesis ([@b1-ehp0113-a00504]; [@b3-ehp0113-a00504]; [@b7-ehp0113-a00504]) and associated suppression of hormone production (testosterone, insulin-like factor 3) by the fetal testis ([@b10-ehp0113-a00504]; [@b17-ehp0113-a00504]; [@b18-ehp0113-a00504]). One indication that the phthalate-exposed pups are "undermasculinized" is that they exhibit a reduction in anogenital distance (AGD) ([@b2-ehp0113-a00504]; [@b4-ehp0113-a00504]; [@b9-ehp0113-a00504]; [@b19-ehp0113-a00504]). AGD in male rats is normally about twice that in females, and a similar sex difference is evident in humans ([@b12-ehp0113-a00504]). This difference is a direct reflection of growth-stimulating actions of androgens, such as testosterone, on the perineum in fetal life; it is therefore an indicator of the level of androgen action in the fetus and thus of the masculinization process. Reduced AGD = reduced androgen levels or action.

Reduction in AGD in rats occurs after dosing the pregnant mothers with phthalates at concentrations \> 250 mg/kg/day ([@b2-ehp0113-a00504]; [@b9-ehp0113-a00504]; [@b19-ehp0113-a00504]). Humans are exposed to a range of phthalates ([@b6-ehp0113-a00504]; [@b14-ehp0113-a00504]), with urinary concentrations of the primary metabolites of key phthalates in the range of 3--40 μg/L (150--1,000 μg/L for monoethyl phthalate). Although the phthalate dose administered to rats and the concentration of urinary phthalate metabolites in humans is difficult to compare directly, the consensus view has been that humans are not exposed to phthalates at levels capable of affecting fetal testis hormone production and masculinization in rats. [@b16-ehp0113-a00504] challenge this view by showing a negative relationship between the anogenital index (AGI) in boys 2--30 months of age and the level of phthalate metabolites in maternal urine during the index pregnancy. At face value, this suggests that phthalates have similar adverse effects on fetal testosterone production in humans as they do in rats. However, this effect must occur at lower levels of phthalate exposure in humans, because reduced AGI was found in boys born to mothers with phthalate levels similar to those found in about 25% of the U.S. population ([@b14-ehp0113-a00504]). If this interpretation is correct, it provides a strong likelihood that phthalate exposure in humans is one potential cause of TDS disorders, a conclusion that has widespread public health implications. So how certain can we be about this interpretation?

[@b16-ehp0113-a00504] show an association between maternal phthalate exposure and AGI in boys---they do not show that one caused the other or that the phthalates caused reduced testosterone production. They also do not show that phthalate exposure caused abnormalities (all boys were "normal"), although the collateral finding that boys with a lower AGI had a higher incidence of cryptorchidism and reduced penis size, when compared with boys with a higher AGI, is consistent with an abnormal reduction in testosterone levels. Measurement of urinary, salivary, or blood (e.g., cord blood) testosterone levels in relation to AGI in future studies should help to clarify this issue, as should establishment of more detailed normative data for AGI in boys and girls and the evaluation of AGI in boys with established evidence of deficient androgen action, such as those with hypospadias.

The findings of [@b16-ehp0113-a00504] need to be confirmed independently. This is not a criticism of the quality of the study (which is excellent) but a standard requirement of good science. Better understanding of the comparative fetal exposure of humans to phthalates and those in the experimental studies in rats, for example, by comparison of phthalate metabolite levels in amniotic fluid, would also be instructive. What is also urgently needed is improved knowledge about how humans, in particular pregnant women, are exposed to phthalates ([@b14-ehp0113-a00504]). What are the most important routes: air, water, diet, or personal care products? One sensible, precautionary response to the present findings is for women who are planning a pregnancy to minimize their exposure to phthalates, but they cannot be guided how to do so unless we know their primary routes of exposure.

Two final notes of caution for readers who consider it wise to assume that phthalates cause TDS in humans. First, the association of AGI with phthalate exposure could be fortuitous; for example, the same lifestyle practices that expose a woman to phthalates might themselves cause the reduction in testosterone/AGI or expose her to other factors that cause this effect. Second, the TDS hypothesis argues that any factor that causes testicular dysgenesis (mal-development) is likely to result in TDS disorders, and this includes well-established genetic disorders ([@b15-ehp0113-a00504]); it is also likely to be affected by maternal lifestyle. Therefore, phthalates will not be the only cause of TDS. For the moment, we do not even know they are a cause, but it is undoubtedly a possibility that deserves urgent further study.
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